Syros Pharmaceuticals Inc (SYRS)
5.435
-0.04
(-0.82%)
USD |
NASDAQ |
May 17, 16:00
5.435
0.00 (0.00%)
After-Hours: 20:00
Syros Pharmaceuticals SG&A Expense (Quarterly): 6.266M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 6.266M |
| December 31, 2023 | 5.888M |
| September 30, 2023 | 7.764M |
| June 30, 2023 | 7.225M |
| March 31, 2023 | 7.405M |
| December 31, 2022 | 7.329M |
| September 30, 2022 | 8.076M |
| June 30, 2022 | 6.945M |
| March 31, 2022 | 6.949M |
| December 31, 2021 | 6.43M |
| September 30, 2021 | 5.346M |
| June 30, 2021 | 5.52M |
| March 31, 2021 | 5.739M |
| December 31, 2020 | 5.892M |
| September 30, 2020 | 5.151M |
| June 30, 2020 | 5.133M |
| March 31, 2020 | 5.149M |
| December 31, 2019 | 6.401M |
| September 30, 2019 | 5.016M |
| Date | Value |
|---|---|
| June 30, 2019 | 5.195M |
| March 31, 2019 | 4.865M |
| December 31, 2018 | 4.372M |
| September 30, 2018 | 3.876M |
| June 30, 2018 | 3.841M |
| March 31, 2018 | 4.075M |
| December 31, 2017 | 3.74M |
| September 30, 2017 | 3.593M |
| June 30, 2017 | 3.472M |
| March 31, 2017 | 3.086M |
| December 31, 2016 | 2.919M |
| September 30, 2016 | 2.633M |
| June 30, 2016 | 2.54M |
| March 31, 2016 | 2.371M |
| December 31, 2015 | 2.311M |
| September 30, 2015 | 1.598M |
| June 30, 2015 | 0.984M |
| March 31, 2015 | 0.836M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
5.016M
Minimum
Sep 2019
8.076M
Maximum
Sep 2022
6.241M
Average
6.079M
Median
SG&A Expense (Quarterly) Benchmarks
| PAVmed Inc | 10.99M |
| Moderna Inc | 274.00M |
| Altimmune Inc | 5.312M |
| iBio Inc | 2.961M |
| Lixte Biotechnology Holdings Inc | 0.8478M |